Tag: malignant pleural mesothelioma

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy ...

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy ...

1. Disease control was reported in over half of the patients treated with abemaciclib 2. Most common adverse events included ...

1. Overall survival was 6.9 months in the placebo group and 10.2 months in the nivolumab group. 2. Progression free ...

1. Compared to the gemcitabine with placebo group, the gemcitabine with ramucirumab group had longer overall survival as a potential ...

1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group (14.1 ...

1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group ...

Malignant pleural mesothelioma is a devastating cancer, with survival rates ranging from as low as 17% to 46%. Diagnosis and/or ...